George Martin
Director/Board Member bei TRISALUS LIFE SCIENCES, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
George Kelly Martin founded Brandon Point Industries Ltd.
in 2014, where he is working as Director from 2014.
Mr. Martin also currently works at Elan Pharmaceuticals LLC, as President & Chief Executive Officer from 2003, Malin Life Sciences Holdings Ltd., as Chief Executive Officer, Radius Pharmaceuticals, Inc., as Chief Executive Officer, Serenus Biotherapeutics, Inc., as Chairman from 2015, Wavebreak Therapeutics Ltd., as Executive Chairman, Transition Bio, Inc., as Executive Chairman, and TriSalus Life Sciences, Inc., as Independent Director from 2023.
Mr. Martin also formerly worked at Elan Corp.
Plc, as President, Chief Executive Officer & Director in 2013, Radius Health, Inc., as President, Chief Executive Officer & Director from 2020 to 2022, Malin Corp.
Plc, as Chief Executive Officer & Executive Director from 2015 to 2017, Elan Pharma Ltd., as Chief Executive Officer, Questcor Pharmaceuticals, Inc., as Director from 2013 to 2014, Viamet Pharmaceuticals, Inc., as Director, NVN Liquidation, Inc., as Non-Executive Director in 2020, Viamet Pharmaceuticals Corp., as Independent Director, Kymab Ltd., as Non-Executive Director, Poseida Therapeutics, Inc., as Director, and Immunocore Holdings Plc, as Non-Executive Director.
Mr. Martin received his undergraduate degree from Princeton University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 03.04.2024 | 247 185 ( 0,94% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von George Martin
| Unternehmen | Position | Beginn |
|---|---|---|
| TRISALUS LIFE SCIENCES, INC. | Director/Board Member | 10.08.2023 |
Transition Bio, Inc.
 Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles. | Chairman | - |
Radius Pharmaceuticals, Inc.
 Radius Pharmaceuticals, Inc. Medical DistributorsDistribution Services Part of Radius Health, Inc., Radius Pharmaceuticals, Inc. supplies and distributes pharmaceutical products. The private company is based in Waltham, MA. The CEO of the company is George Kelly Martin. | Chief Executive Officer | - |
Wavebreak Therapeutics Ltd.
 Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Chairman | - |
Malin Life Sciences Holdings Ltd.
 Malin Life Sciences Holdings Ltd. Financial ConglomeratesFinance Part of Malin Corp. Plc, Malin Life Sciences Holdings Ltd. functions as an investment holding Irish company. The private company is based in Dublin, Ireland. The CEO of the company is George Kelly Martin. | Chief Executive Officer | - |
Serenus Biotherapeutics, Inc.
 Serenus Biotherapeutics, Inc. Medical DistributorsDistribution Services Serenus Biotherapeutics, Inc. distributes and manufactures pharmaceutical drug products. The company is headquartered in San Francisco, CA. | Chairman | 11.06.2015 |
Brandon Point Industries Ltd.
 Brandon Point Industries Ltd. Medical/Nursing ServicesHealth Services Brandon Point Industries Ltd. operates as a life sciences company. It focuses on healthcare. The company was founded in 2014 by George Kelly Martin and John Oliver Thomas Given and is headquartered in Dublin, Ireland. | Founder | 01.01.2014 |
Elan Pharmaceuticals, LLC
 Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Chief Executive Officer | 03.02.2003 |
Ehemalige bekannte Positionen von George Martin
| Unternehmen | Position | Ende |
|---|---|---|
| RADIUS HEALTH, INC. | Chief Executive Officer | 01.08.2022 |
| ░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von George Martin
| Princeton University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| NVN LIQUIDATION, INC. | Health Technology |
| MALIN CORPORATION PLC | Health Technology |
| POSEIDA THERAPEUTICS, INC. | Health Technology |
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| TRISALUS LIFE SCIENCES, INC. | Health Technology |
| Private Unternehmen | 14 |
|---|---|
Elan Corp. Plc
 Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
Questcor Pharmaceuticals, Inc.
 Questcor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Questcor Pharmaceuticals, Inc. was engaged in development, marketing and sale of prescription drugs. It operated as a biopharmaceutical company which focuses on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The company's primary product was H.P. Acthar Gel, an injectable drug for the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. Questcor Pharmaceuticals was founded in September 1992 and was headquartered in Anaheim, CA. | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Health Technology |
Elan Pharmaceuticals, LLC
Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Health Technology |
Viamet Pharmaceuticals Corp.
 Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Health Technology |
Elan Pharma Ltd.
 Elan Pharma Ltd. Pharmaceuticals: MajorHealth Technology Elan Pharma Ltd. supplies and markets pharmaceutical products. It offers neuroscience-based biotechnology services. The company is headquartered in Hampshire, UK | Health Technology |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Brandon Point Industries Ltd.
Brandon Point Industries Ltd. Medical/Nursing ServicesHealth Services Brandon Point Industries Ltd. operates as a life sciences company. It focuses on healthcare. The company was founded in 2014 by George Kelly Martin and John Oliver Thomas Given and is headquartered in Dublin, Ireland. | Health Services |
Malin Life Sciences Holdings Ltd.
Malin Life Sciences Holdings Ltd. Financial ConglomeratesFinance Part of Malin Corp. Plc, Malin Life Sciences Holdings Ltd. functions as an investment holding Irish company. The private company is based in Dublin, Ireland. The CEO of the company is George Kelly Martin. | Finance |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Radius Pharmaceuticals, Inc.
Radius Pharmaceuticals, Inc. Medical DistributorsDistribution Services Part of Radius Health, Inc., Radius Pharmaceuticals, Inc. supplies and distributes pharmaceutical products. The private company is based in Waltham, MA. The CEO of the company is George Kelly Martin. | Distribution Services |
Transition Bio, Inc.
Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles. | Health Technology |
Serenus Biotherapeutics, Inc.
Serenus Biotherapeutics, Inc. Medical DistributorsDistribution Services Serenus Biotherapeutics, Inc. distributes and manufactures pharmaceutical drug products. The company is headquartered in San Francisco, CA. | Distribution Services |
